About this toolkit

Copyright information for the source of the content within this app/website is shown below.

Copyright of this guideline is retained by SIGN. Users may download or print copies for their own use and for the purpose of implementation.

This review is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence.  This allows for the copy and redistribution of SIGN guidelines as long as SIGN is fully acknowledged and given credit.  The material must not be remixed, transformed or built upon in any way.  To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/.

Please cite the guideline as: Scottish Intercollegiate Guidelines Network (SIGN).  SIGN 146: Cutaneous melanoma.  Edinburgh: SIGN; 2023. [cited dd mmm yyyy]  Available from: https://www.sign.ac.uk/our-guidelines/cutaneous-melanoma/

The content within this app/website is based on current evidence and best practice, however it is intended to be applied alongside sound clinical judgement.  As such, Healthcare Improvement Scotland is not responsible or liable for any diagnosis or management decision made on the basis of the information provided via this app/website.

Use of this app within patient care settings should always be in accordance with local policies and guidance with regard to clinical practice and mobile device usage.

Healthcare Improvement Scotland is not responsible for the content of any external websites listed, nor do they endorse any commercial product or service mentioned or advised on in any of these websites.

All use of this resource is subject to Scots law and the jurisdiction of the Scottish courts and is subject to this disclaimer.  Any views given on the app/website are not necessarily those of Healthcare Improvement Scotland or anyone connected with us.

Ailsa Stein - Programme Manager, SIGN.  ailsa.stein@nhs.scot

Kirsty Littleallan - Administrative Officer, SIGN. kirsty.littleallan@nhs.scot

This toolkit is based on SIGN 146: Cutaneous melanoma which includes details on how the guideline was produced. Further information on SIGN methodology is available from SIGN 50: a guideline developer's handbook

Authorship

The content in this toolkit has been developed by the SIGN guideline group for SIGN 146: Cutaneous melanoma

Review and approval

Content has been reviewed and approved in line with the SIGN editorial governance process.

Final content was signed off by the SIGN Programme Lead.

The content will be considered for update 3 years from publication. Any minor updates brought to the  attention will be dealt with on an "as needed" basis.

Updates will be reviewed and approved in line with the SIGN editorial governance process.

Content will be updated using the guideline development processes outlined in the SIGN methodology manual, SIGN 50: a guideline developer's handbook.

The content was reviewed by the clinicians and people with lived experience on the guideline development group.

The SIGN guideline was available for peer review prior to publication. All comments received were addressed and responses published on the SIGN website. The guideline was reviewed by clinical experts from SIGN Council as part of the editorial process.

The content of this toolkit was reviewed by the SIGN editorial team and signed off by the SIGN Programme Lead.

Content has been checked for accessibility in line with the relevant RDS standard operating procedure.

The email for the SIGN Programme Manager is available in the "Key contacts" section above and can be used to highlight any feedback or complaints.

Any messages received through the RDS Feedback form will also be forwarded to the Programme Manager.

The Programme Manager will address the feedback. If it requires significant amendments, it will be referred to the SIGN senior management team for consideration for the SIGN work programme.

The toolkit has been risk assessed, and mitigations put in place where required.

Prior to publication the toolkit was user tested by the guideline development group.